• Pharvaris recently announced that one oral presentation and seven flash talk/poster presentations on its oral HAE therapy deucrictibant were accepted for the European Academy of Allergy and Clinical Immunology Congress 2026, with materials to be shared via its investor website.
• The update also confirms that Pharvaris is preparing marketing authorization filings for deucrictibant and progressing multiple Phase 3 programs, positioning the drug as a potentially comprehensive treatment option across on-demand and prophylactic hereditary and acquired angioedema settings.
• We’ll now examine how this cluster of Phase 3 and long-term safety data disclosures for deucrictibant shapes Pharvaris’ investment narrative.

We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

What Is Pharvaris' Investment Narrative?

To own Pharvaris, you need to believe that deucrictibant can successfully transition from promising data into approved, widely used oral therapies across both on-demand and prophylactic angioedema settings, before the cash runway tightens. The new EAACI 2026 abstract cluster reinforces that the near-term story still revolves around regulatory filings for the immediate-release capsule and pivotal Phase 3 readouts for the extended-release tablet, rather than shifting the core catalysts. It adds depth to the cardiovascular safety, long-term prophylaxis and patient-reported outcomes narrative, which may matter at the margins when regulators and payers scrutinize the totality of evidence. However, it does not remove key risks: ongoing losses, reliance on a single asset across multiple indications, and the potential for any late-stage setback to hit a stock that has already delivered a very strong multi-year return.

However, there is one trial-related risk here that current shareholders cannot ignore. Pharvaris' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Simply Wall St Community members currently cluster around a single fair value estimate near US$46.50, yet Task 1 highlights how pending Phase 3 readouts and continued losses could still reshape expectations and test confidence in Pharvaris’ path forward.

Explore another fair value estimate on Pharvaris - why the stock might be worth just $46.50!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Pharvaris research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Pharvaris research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pharvaris' overall financial health at a glance.

Contemplating Other Strategies?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Uncover the next big thing with 23 elite penny stocks that balance risk and reward.
• Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.